SequelSEC

International Stem Cell CORP ISCO

Pharmaceutical Preparations · CIK 0001355790 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$9.10M
Fiscal year ended 2025-12-31
Operating income
-$267.00K
Fiscal year ended 2025-12-31
Free cash flow
-$35.00K
Fiscal year ended 2025-12-31

International Stem Cell CORP (ISCO) reported revenue of $9.10M and net income of -$418.00K for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from International Stem Cell CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

International Stem Cell CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$9.10M$9.08M$7.79M$8.18M$7.18M$7.13M$9.47M$11.09M$7.46M$7.16M
Cost of revenue$4.03M$3.76M$3.18M$3.27M$2.94M$2.78M$3.93M$4.07M$2.12M$1.94M
Gross profit$5.07M$5.32M$4.61M$4.91M$4.24M$4.35M$5.54M$7.02M$5.33M$5.22M
Operating income-$267.00K-$68.00K-$663.00K-$183.00K-$1.92M-$2.82M-$5.73M-$3.47M-$4.94M-$4.85M
Net income-$418.00K-$209.00K-$131.00K-$331.00K-$899.00K-$2.72M-$4.26M-$2.13M-$6.07M-$1.08M
Research & development$684.00K$657.00K$511.00K$492.00K$695.00K$988.00K$1.39M$2.40M$2.66M$2.86M
Weighted-average diluted sharesshares 8.00Mshares 8.00Mshares 8.00Mshares 8.00Mshares 7.83MUnavailableUnavailableshares 6.39Mshares 4.16Mshares 3.19M
Pretax income-$418.00K-$209.00K-$131.00K-$331.00KUnavailableUnavailableUnavailable-$2.13M-$6.07M-$1.08M
Income tax expense$0$0UnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0
Diluted EPS$-0.05$-0.03$-0.02$-0.04$-0.11UnavailableUnavailable$-0.33$-1.46$-0.34
Selling, general & administrative$4.65M$4.73M$4.76M$4.60M$5.47M$6.18M$9.88M$8.10M$7.62M$7.22M
General & administrative$3.53M$3.52M$3.51M$3.36M$4.08M$4.42M$7.20M$5.47M$5.21M$4.69M
Selling & marketing$1.12M$1.22M$1.25M$1.24M$1.38M$1.76M$2.68M$2.63M$2.40M$2.53M

Balance

International Stem Cell CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$304.00K$110.00K
Total assets$4.82M$5.17M$5.39M$5.14M$4.95M$5.29M$6.62M$7.80M$6.86M$7.04M
Current assets$3.41M$3.56M$3.52M$2.96M$2.33M$2.18M$3.45M$3.77M$2.86M$2.49M
Total liabilities$4.58M$4.80M$5.28M$5.36M$5.23M$5.32M$5.21M$5.26M$4.80MUnavailable
Current liabilities$4.58M$4.69M$4.83M$4.64M$4.28M$1.48M$1.91M$5.08M$4.80M$3.60M
Total equity incl. NCI-$4.06M-$3.93M-$4.19M-$4.52M-$4.59M-$4.33M-$2.89M$2.54M$2.06M$3.44M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$1.51M$1.15M$1.26M$1.38M$1.18M$917.00K$1.25M$1.50M$1.31M$1.39M
Accounts receivable$723.00K$1.06M$574.00K$747.00K$844.00K$403.00K$1.52M$651.00K$465.00K$574.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$168.00K$186.00K$364.00K$322.00K$508.00K$360.00K$654.00K$458.00K$830.00K$841.00K

Cash flow

International Stem Cell CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$8.00K$13.00K$929.00K$332.00K-$1.30M-$341.00K-$1.40M-$1.08M-$2.14MUnavailable
Capital expenditures$43.00K$166.00K$80.00K$1.00K$23.00K$28.00K$164.00K$185.00K$112.00K$231.00K
Investing cash flow-$45.00K-$171.00K-$83.00K-$11.00K-$45.00K-$108.00K-$494.00K-$661.00K-$864.00KUnavailable
Financing cash flow-$200.00K-$200.00KUnavailable$250.00K$824.00K$654.00K$1.30M$2.51M$3.20MUnavailable
Net change in cash-$237.00K-$358.00K$846.00K$571.00K-$518.00K$205.00K-$591.00K$771.00K$194.00K-$422.00K
Stock-based compensation$288.00K$466.00K$464.00K$399.00K$644.00K$1.28M$2.09M$1.68M$1.38M$972.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$219.00K$206.00K$194.00K$218.00K$262.00K$253.00K$285.00K$308.00K$326.00K$331.00K

Derived

International Stem Cell CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$35.00K-$153.00K$849.00K$331.00K-$1.32M-$369.00K-$1.56M-$1.27M-$2.25MUnavailable
Gross margin55.7%58.6%59.2%60.0%59.1%61.0%58.5%63.3%71.5%72.9%
Operating margin-2.9%-0.7%-8.5%-2.2%-26.8%-39.5%-60.5%-31.3%-66.3%-67.7%
FCF margin-0.4%-1.7%10.9%4.0%-18.4%-5.2%-16.5%-11.4%-30.2%Unavailable
SBC / revenue3.2%5.1%6.0%4.9%9.0%17.9%22.0%15.2%18.6%13.6%
Current ratio0.74x0.76x0.73x0.64x0.54x1.47x1.80x0.74x0.59x0.69x
Revenue YoY growth0.2%16.6%-4.8%14.0%0.7%-24.7%-14.6%48.7%4.1%Unavailable
Net margin-4.6%-2.3%-1.7%-4.0%-12.5%-38.2%-45.0%-19.2%-81.4%-15.1%
R&D / revenue7.5%7.2%6.6%6.0%9.7%13.9%14.6%21.6%35.6%39.9%
CapEx / revenue0.5%1.8%1.0%0.0%0.3%0.4%1.7%1.7%1.5%3.2%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ISCO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

7 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2025-12-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-12-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2023-12-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2022-12-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2021-12-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2020-12-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2019-12-31

Difference 4300000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.